Screening for type 2 diabetes in a high-risk population: Study design and feasibility of a population-based randomized controlled trial

BMC Public Health

Volumn 12, Issue 1, 2012, Pages

  Klijs, Bart ^a   Otto, Suzie J ^a   Heine, Robert J ^b,c   Van Der Graaf, Yolanda ^d   Lous, Jan J ^e   De Koning, Harry J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e STAR Medical Diagnostic Center   (Netherlands)

Author keywords

Abdominal obesity; Early detection; Screening; Type 2 diabetes; Waist circumference

Indexed keywords

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; WAIST CIRCUMFERENCE;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; OBESITY, ABDOMINAL; RESEARCH DESIGN; RISK ASSESSMENT; WAIST CIRCUMFERENCE;

EID: 84869173840     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-12-671     Document Type: Article

References (40)

1. Global estimates of the prevalence of diabetes for 2010 and 2030. Shaw JE, Sicree RA, Zimmet PZ, Diabetes Res Clin Pract 2010 87 1 4 14 10.1016/j.diabres.2009.10.007 19896746
2. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR, BMJ 2000 321 7258 405 412 10.1136/bmj.321.7258.405 10938048 (Pubitemid 30609442)
3. Cause-specific mortality in a population with diabetes: South Tees Diabetes mortality study. Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM, Diabetes Care 2002 25 1 43 48 10.2337/diacare.25.1.43 11772899 (Pubitemid 41070781)
4. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, Tonkin AM, et al. Circulation 2007 116 2 151 157 10.1161/CIRCULATIONAHA.106. 685628 17576864 (Pubitemid 47057520)
5. World Health Organization, Screening for Type 2 Diabetes-Report of a World Health Organization and International Diabetes Federation meeting Geneva: WHO-Department of Noncommunicable Disease Management 2003
6. Health Council of the Netherlands, Screening for type 2 diabetes The Hague: Health Council of the Netherlands 2004
7. Standards of medical care in diabetes - 2007. American Diabetes A, Diabetes Care 2007 30 Suppl 1 4 S41 17192377
8. International Diabetes Federation: a consensus on Type 2 diabetes prevention. Alberti KG, Zimmet P, Shaw J, Diabet Med 2007 24 5 451 463 10.1111/j.1464-5491.2007.02157.x 17470191 (Pubitemid 46669328)
9. Screening for type 2 diabetes: literature review and economic modelling. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, Williams R, John A, Health Technol Assess 2007 11 17 1 125 iii-iv, ix-xi 17927921
10. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Norris SL, Kansagara D, Bougatsos C, Fu R, Force USPST, Ann Intern Med 2008 148 11 855 868 18519931 (Pubitemid 351786934)
11. Principles and practice of mass screening for disease. Wilson JM, Jungner YG, Public Health Papers No 34 Geneva: World Health Organization 1968 1 163
12. Back to Wilson and Jungner: 10 good reasons to screen for type 2 diabetes mellitus. Sheehy AM, Coursin DB, Gabbay RA, Mayo Clin Proc 2009 84 1 38 42 10.4065/84.1.38 19121253
13. Screening for type 2 diabetes: an update of the evidence. Simmons RK, Echouffo-Tcheugui JB, Griffin SJ, Diabetes Obes Metab 2010 12 10 838 844 10.1111/j.1463-1326.2010.01244.x 20920035
14. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Harris MI, Klein R, Welborn TA, Knuiman MW, Diabetes Care 1992 15 7 815 819 10.2337/diacare.15.7.815 1516497
15. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jonsson B, Laakso M, Malmberg K, et al. Eur Heart J 2007 28 1 88 136 17220161 (Pubitemid 46137814)
16. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbaek A, Sharp SJ, Simmons RK, van den Donk M, Wareham NJ, et al. Lancet 2011 378 9786 156 167 10.1016/S0140-6736(11)60698-3 21705063
17. Bemelmans WJE, Hoogenveen RT, Visscher TLS, Verschuren WMM, Schuit AJ, Toekomstige ontwikkelingen in overgewicht. Inschatting effecten op de volksgezondheid Bilthoven: RIVM 2004
18. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The nurses' health study. Carey VJ, Walters EE, Colditz GA, Solomon CG, Willett WC, Rosner BA, Speizer FE, Manson JE, Am J Epidemiol 1997 145 7 614 619 10.1093/oxfordjournals.aje.a009158 9098178 (Pubitemid 27154864)
19. Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: the Hoorn Study. Snijder MB, Dekker JM, Visser M, Bouter LM, Stehouwer CD, Kostense PJ, Yudkin JS, Heine RJ, Nijpels G, Seidell JC, Am J Clin Nutr 2003 77 5 1192 1197 12716671 (Pubitemid 44858435)
20. Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study. Snijder MB, Zimmet PZ, Visser M, Dekker JM, Seidell JC, Shaw JE, Int J Obes Relat Metab Disord 2004 28 3 402 409 10.1038/sj.ijo.0802567 14724659 (Pubitemid 38296954)
21. Comparison of anthropometric characteristics in predicting the incidence of type 2 diabetes in the EPIC-Potsdam study. Schulze MB, Heidemann C, Schienkiewitz A, Bergmann MM, Hoffmann K, Boeing H, Diabetes Care 2006 29 8 1921 1923 10.2337/dc06-0895 16873804 (Pubitemid 44156654)
22. Rutten GEHM, de Grauw WJC, Nijpels G, Goudswaard AN, Uitewaal PJM, van der Does FEE, Heine RJ, van Ballegooie E, Verduijn MM, Bouma M, NHG-Standaard Diabetes mellitus type 2 M01 NHG: In NHG-Standaarden 2006
23. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Friedewald WT, Levy RI, Fredrickson DS, Clin Chem 1972 18 6 499 502 4337382
24. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, et al. Eur Heart J 2003 24 11 987 1003 10.1016/S0195-668X(03)00114-3 12788299 (Pubitemid 36712275)
25. Effective PSA contamination in the Rotterdam section of the European randomized study of screening for prostate cancer. Otto SJ, van der Cruijsen IW, Liem MK, Korfage IJ, Lous JJ, Schröder FH, de Koning HJ, Int J Cancer 2003 105 3 394 399 10.1002/ijc.11074 12704675 (Pubitemid 36570054)
26. Impairment of health and quality of life in people with large waist circumference. Lean ME, Han TS, Seidell JC, Lancet 1998 351 9106 853 856 10.1016/S0140-6736(97)10004-6 9525361 (Pubitemid 28121172)
27. The burden of mortality of diabetes mellitus in The Netherlands. Baan CA, Nusselder WJ, Barendregt JJ, Ruwaard D, Bonneux L, Feskens EJ, Epidemiology 1999 10 2 184 187 10.1097/00001648-199903000-00018 10069257 (Pubitemid 29093958)
28. Testing at home-the screening of the future? de Koning HJ, Eur J Public Health 2009 19 1 5 6 19126573
29. Identifying people with metabolic syndrome in primary care by screening with a mailed tape measure. A survey in 14,000 people in the Netherlands. van den Donk M, Bobbink IW, Gorter KJ, Salome PL, Rutten GE, Prev Med 2009 48 4 345 50 10.1016/j.ypmed.2009.02.004 19463483
30. Waist circumference home measurement-a device to find out patients in cardiovascular risk. Korhonen PE, Jaatinen PT, Aarnio PT, Kantola IM, Saaresranta T, Eur J Public Health 2009 19 1 95 99 18927187
31. Low yield of population-based screening for Type 2 diabetes in the Netherlands: the ADDITION Netherlands study. Janssen PG, Gorter KJ, Stolk RP, Rutten GE, Fam Pract 2007 24 6 555 561 10.1093/fampra/cmm052 17962235
32. Performance of an NIDDM screening questionnaire based on symptoms and risk factors. Ruige JB, de Neeling JN, Kostense PJ, Bouter LM, Heine RJ, Diabetes Care 1997 20 4 491 496 10.2337/diacare.20.4.491 9096967 (Pubitemid 27143402)
33. Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: the Hoorn Study. Spijkerman AM, Dekker JM, Nijpels G, Jager A, Kostense PJ, van Hinsbergh VW, Bouter LM, Heine RJ, Stehouwer CD, Eur J Clin Invest 2002 32 12 924 930 10.1046/j.1365-2362.2002.01090.x 12534452 (Pubitemid 35478064)
34. Relationship between A1C and glucose levels in the general Dutch population: the new Hoorn study. van 't Riet E, Alssema M, Rijkelijkhuizen JM, Kostense PJ, Nijpels G, Dekker JM, Diabetes Care 2010 33 1 61 66 10.2337/dc09-0677 19808928
35. A cluster-randomised trial of screening for language disorders in toddlers. de Koning HJ, de Ridder-Sluiter JG, Van Agt HM, Reep-Van Den Bergh CM, Van Der Stege HA, Korfage IJ, Polder JJ, Van Der Maas PJ, J Med Screen 2004 11 3 109 116 10.1258/0969141041732229 15333268 (Pubitemid 39274091)
36. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). Roobol MJ, Kirkels WJ, Schroder FH, BJU Int 2003 92 Suppl 2 48 54 14983955 (Pubitemid 38091140)
37. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). van Iersel CA, de Koning HJ, Draisma G, Mali WP, Scholten ET, Nackaerts K, Prokop M, Habbema JD, Oudkerk M, van Klaveren RJ, Int J Cancer 2007 120 4 868 874 10.1002/ijc.22134 17131307 (Pubitemid 46175408)
38. Council of Europe, Common European Framework of Reference for Languages: Learning, Teaching, Assessment Camebridge, UK: Camebridge University Press 2001
39. Tools for predicting the risk of type 2 diabetes in daily practice. Schwarz PE, Li J, Lindstrom J, Tuomilehto J, Horm Metab Res 2009 41 2 86 97 10.1055/s-0028-1087203 19021089
40. Estimating the potential population impact of stepwise screening strategies for identifying and treating individuals at high risk of Type 2 diabetes: a modelling study. Chamnan P, Simmons RK, Khaw KT, NJ Wa, Griffin S, Diabet Med 2012 29 7 893 904 10.1111/j.1464-5491.2012.03609.x 22340130